TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04643028

Intervention type: OTHER
Group type: OTHER
Intervention: Home exercise
Description: Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Mulligan mobilization
Description: Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.

Intervention type: OTHER
Group type: OTHER
Intervention: Cervical stabilization
Description: Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
Study: NCT02054897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly, administrated subcutaneously (s.c. under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly, administrated subcutaneously (s.c. under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once weekly, administrated subcutaneously (s.c. under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once weekly, administrated subcutaneously (s.c. under the skin)
Study: NCT00996268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2212836
Description: Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2212836
Description: Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
Study: NCT00960843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraband pressure recording system
Description: Intraband pressure will be measured by a pressure recording system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Adjustment
Description: Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
Study: NCT03377530

Intervention type: DIAGNOSTIC_TEST
Intervention: Ways to prevent these infections.
Description: The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections.
Study: NCT01173224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study: NCT05313204

Intervention type: OTHER
Intervention: Moderate-intensity cardiovascular exercise
Description: The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.

Intervention type: OTHER
Intervention: Moderate-intensity cardiovascular exercise
Description: The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.

Intervention type: OTHER
Intervention: Moderate-intensity cardiovascular exercise
Description: The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.

Intervention type: OTHER
Intervention: Moderate-intensity cardiovascular exercise
Description: The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
Study: NCT03797755

Intervention type: RADIATION
Intervention: palliative radiotherapy
Description: Radiotherapy for palliating symptoms in stage IV cancer patients
Study: NCT00970281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Intramuscular Olanzapine
Description: Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
Study: NCT06374030

Intervention type: PROCEDURE
Intervention: Endotracheal intubation
Description: All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
Study: NCT04531228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE-HAIC plus lenvatinib
Description: chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
Study: NCT03233620

Intervention type: OTHER
Group type: OTHER
Intervention: Knee arthroplasty
Description: Effectiveness of knee arthroplasty surgery.
Study: NCT03213119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.
Description: Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.
Description: Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.
Description: Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
Study: NCT02756325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
Study: NCT03413631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal mentalization intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal obstetric treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal obstetric treatment as usual
Study: NCT03012477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Wee1 tyrosine kinase inhibitor
Study: NCT01583777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days.
Study: NCT00576381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
Study: NCT02247479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Participants will receive 10 mg dose of lampalizumab administered intravitreally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Participants will receive 10 mg dose of lampalizumab administered intravitreally.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
Study: NCT04326777

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ballon pulmonary angioplasty
Description: Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
Study: NCT00564525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Medication taken for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medication taken for 4 weeks
Study: NCT03466190

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium plate fixation
Description: Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom made PEEK plate fixation
Description: Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
Study: NCT01443065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: 6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG102
Description: 10mg/kg over 60 mn every 2 weeks up to progression or toxicity
Study: NCT03363074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole
Description: A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser
Description: A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
Study: NCT03403764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Intention
Study: NCT00821392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Febuxostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Study: NCT00718159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
Study: NCT05653596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive intervention
Description: This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
Study: NCT04989036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
Study: NCT04634448

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interval appendectomy
Description: interval appendectomy at 2 to 3 months after the initial non-operative treatment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Follow-up MRI at 1 year
Description: follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
Study: NCT04322071

Intervention type: OTHER
Intervention: Interview
Description: Qualitative interviews only

Intervention type: OTHER
Intervention: Interview
Description: Qualitative interviews only
Study: NCT03335371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399
Description: Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399
Description: Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Study: NCT01055964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT03361371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battery operated nasal aspirator
Description: Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Suction bulb
Description: Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
Study: NCT03614377

Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
Study: NCT01591707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISC+PRT Intervention
Description: Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
Study: NCT02070744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film coated tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film coated tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film coated tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661
Description: Tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661
Description: Tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Ivacaftor
Description: Film coated tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Ivacaftor
Description: Film coated tablet, oral use
Study: NCT01566409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
Study: NCT04101149

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT04089709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-arm Exercise
Description: Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
Study: NCT01684358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sino-implant (II)
Description: Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sino-implant (II)
Description: Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
Study: NCT01604044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropur 150 a day
Description: one subcutaneous injection a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f 150 plus Luveris 150
Description: one subcutaneous injection a day